Download the .pdf here -

29 Pages·2013·0.98 MB·English

by  Alasdair Stamps

In ternationalising UK Lif e Sciences

UK Delegation

Members of the UK delegation are listed
here alphabetically with profiles.

Further information is available at the UK
stand #68.

A list of all UK based companies attending
the conference is also provided on pages
23-24, sorted by company type.

Also available online at: http://beu13.biopartner.co.uk/search

BIO-Europe 2013
____________________________________________________________

INDEX

Page #

Introduction 2

Biopartner UK 3

Partner Organisations 3

UK Delegation 5

All Attending UK Companies 23

Whereas every effort has been made to ensure that the information given in this
document is accurate, BioPartner UK accepts no liability for any errors, omissions or
misleading statements.
1
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________
Introduction

We are delighted to bring 60+ UK companies to Bio-Europe 2013, and to
support an additional 150 who are independently registered. Visit us at
booth 68 to find out more about UK expertise and make contact with
companies attending from the UK.

The UK is one of the world’s strongest and most productive Life Sciences
economies; it attracts almost 10% of the world’s pharmaceutical R&D
funding and is acknowledged as the gateway to Europe.

At Bio-Europe 2013, we have more than 200 companies from the UK
looking to forge profitable relationships. The UK is a natural trading
partner for Life Sciences companies looking for innovative
collaborations, access to academic excellence and entry to the European
market.

The UK provides a uniquely fertile environment for the Life Sciences
industry where businesses thrive. In the UK, innovation flourishes and is
easy to commercialise; industry collaborates with academia and the
health service; people are highly skilled and the Government is
supportive.

The UK also continues to benefit from a globally admired regulatory
regime, with two internationally recognised product approval agencies
being based there. Small wonder, then, that the UK is a world-class
trading partner in Life Sciences, as well as a leading investment location
for Life Sciences businesses.

Representatives of BioPartner UK, The UK BioIndustry Association (BIA),
UK Trade & Investment and the London Mayor’s Office will be present
and available at BIO-Europe to discuss how we can help maximise your
business potential.

2
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________

BioPartner UK
Lin Bateson, Executive Director
Alasdair Stamps, Executive Director
Della Bateson-Chaffe, Administrator

BioPartner UK is an independent, accredited trade organisation, promoting
international partnering for trade, investment and collaborations with UK Life
Sciences companies. Operating both independently and in partnership with the
UK government and major UK networks and associations, BioPartner assists
SMEs to exhibit overseas, and supports start-ups through the BiotechNet team
of consultants. Through the BioPartnership Programme, members benefit from
discounts negotiated with partner organisations and event providers, and from
shared experiences.

BioPartner leads the UK Delegation at Bio-Europe 2013.
For more information see: www.biopartner.co.uk
Tel: [phone]
Email: [email protected]

Exhibiting at Booth 68

Partner Organisations

UK BioIndustry Association (BIA)
Steve Bates, Chief Executive Officer
Alastair Carrington, Business Development Executive

Established in 1989, the BIA (BioIndustry Association) exists to encourage and
promote a financially sound and thriving bioscience sector within the UK
economy and concentrates its efforts on emerging enterprise and the related
interests of companies with whom such enterprise trades.

With over 300 members, the BIA supports a wide range of sectors, majoring on
the human health benefits of the technology and represents the interests of
these innovative companies to a broad section of stakeholders from patient
groups to politicians, advancing its members interests both within the UK and
internationally to create a healthy UK bioscience sector which benefits society.

For further information, please go to www.bioindustry.org
3
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________

UK Trade & Investment (UKTI) is the government department that helps UK
based companies succeed in international markets and assists overseas
companies to bring high quality investment to the UK’s dynamic economy.
UKTI employs approximately 2,331 staff, of whom 1,279 are overseas and 1,000
are in the UK. We operate in 162 locations, in 96 markets. Staff overseas are
based in British embassies and other diplomatic offices around the world.
Some of the UK companies featured in this directory have been supported by
UKTI grant funding under the Tradeshow Access Programme (TAP).

www.ukti.gov.uk

UK Trade & Investment Vienna
Verena Wasenegger, Trade Officer
British Embassy, Jaurèsgasse 12, 1030 Vienna
Tel: [phone]
E-mail: [email protected]

UK Trade & Investment London
Christopher Parsons, International Trade Advisor

UKTI London's private sector International Trade Advisers support London
based companies to develop their business internationally. This is achieved via
provision of advice, training and delivery of UKTI services.

Supported by the Mayor's Export Program UKTI London is bringing a trade
mission to Bio-Europe. Kit Malthouse the Deputy Mayor of London for Business
and Enterprise will be meeting the mission delegates at a networking breakfast
on Tuesday Nov 5th.

www.ukti.gov.uk/london
10-12 Queen Elizabeth Street, London SE1 2JN
Tel: [phone]
E-mail: [email protected]
4
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________
UK Delegation

Members of the UK delegation are listed alphabetically with profiles, followed
by a list of UK-based organisations (by company name and then by company
type) attending the conference.

Whereas every effort has been made to ensure that the information given in
this document is accurate, BioPartner UK accepts no liability for any errors,
omissions or misleading statements, and no warranty is given or responsibility
accepted as to the standing of any individual, firm, company or other
organisation mentioned. Data was sourced from the Bio-Europe 2013
partnering website, and all UK companies registered up to 22nd October 2013
are included.

Advocates Pharmaceutical & Healthcare
Angelina Fisher, Director of Corporate Affairs

Advocates Ltd., Pharmaceutical & Healthcare is a global Programme Management and
Technical Support Organisation based in Scotland, USA and Hong Kong. Clients include
universities, virtual & start-up companies, biotechs, pharmaceutical companies,
healthcare organisations and investors involved in developing cures for clinical disorders
on a regional basis and with a global focus.

Since 2002, it has been our mission to “accelerate the development pathway towards
healthier, extended lives through our competence and capacity to address drug
development challenges”.
As a testament to this, our team of scientists, project managers & technical
professionals have provided `hands on’ technical support to 17 drug development
programmes from discovery to our clients required endpoint, all of which have met their
development objectives, whilst maintaining focus on delivery of commercial objectives &
investment opportunities.

Discovery to Market Key Services include:
· Grant Funding Support
· Technical Due Diligence / Investor Support
· Project Management
· Discovery & Pre-Clinical Support
· Pharmaceutical Development CMC
· Quality Management
· Regulatory Preparation, Submission & Liaison
· Operational / Commercial CMC
· Supplies / Logistics Management
· Clinical Support
· Medical Devices Expertise
5
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________

Benefits to our Clients:
· Proven expertise of successfully managing development programmes
· Experienced in all compound classes, the majority of therapeutic areas and routes of
administration
· Experts in CMC (Chemistry, Manufacturing & Controls)
· Credible relationships with national regulatory agencies
· Trustworthy relationships with funding bodies
· Bases in UK, USA & HK / trade in local currencies
· We care “caring is a powerful business advantage”

www.advocates.ltd.uk

Almac Group
Stephen Barr, Managing Director
Rick Dyer, Business Development Manager
Glyn Allsop, Business Development Manager
Helen McKeever, Programme Manager
Robert Grundy, Director Research Alliances, Almac Discovery Ltd
Simon Lawrence, VP, Business Development, Galen Ltd

Almac provides a comprehensive range of integrated services from research through to
commercialisation. Almac is a financially stable, privately owned organisation with over
3,300 employees located within the US and UK. Over 95% of work is repeat business,
testament itself to the quality, innovation, efficiency and the high level of customer
satisfaction provided.
Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development: Companion Diagnostic Development, Genomic
Services, Bioinformatics Consultancy, Proprietary Discovery Arrays
API Services & Chemical Development: API Development & Manufacture, Peptide &
Protein Technology, Accelerated First in Man Solution, Solid State Services, Isotope
Chemistry, Biocatalysis
Pharmaceutical Development: Preformulation & Early Stage Development, Scale Up
and Late Stage Development, Clinical Trial Manufacture, Contained Development &
Manufacture
Analytical Services: Physical & Chemical Characterisation, Method Development &
Validation, API & Drug Product Testing, Stability Testing
Clinical Trial Supply: Comparator Blinding, Packaging & Labelling, QP Release, Global
Distribution & Supply Chain Management
Clinical Technologies: IVR / Web, ePRO, Statistical Services
Commercial Services: Manufacturing & Packaging, Product Launch & Distribution

www.almacgroup.com
Exhibiting at Booth 64
6
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________

Albany Molecular Research (AMRI)
Mr Ian Trelfa, Business Development Manager

For over 21 years AMRI has demonstrated its adaptability as the pharmaceutical
and biotechnology industries have undergone tremendous change in response
to multiple challenges. This experience, a track record of success and locations
in the United States, Europe and Asia now provides our customers with
SMARTSOURCINGTM, a full range of value-added opportunities providing
customers informed decision-making, enhanced efficiency and more successful
outcomes at all stages of the pipeline.
AMRI (NASDAQ: AMRI), provides scientific services, technologies and products
focused to the pharmaceutical industry since 1991. The Company’s core
business consists of a fee-for-service contract services platform encompassing
drug discovery, development and manufacturing services.

www.amriglobal.com

Autifony Therapeutics
Dr Barbara Domayne-Hayman, Chief Business Officer

Autifony Therapeutics is developing pharmaceutical treatments for hearing
disorders, which affect a significant proportion of the population. Autifony ‘s
approach is focused on Kv3 potassium channel modulation, a novel mechanism
of action. These ion channels regulate neuronal activity within the auditory
system, and our new drugs aim to treat age related hearing loss and tinnitus.
The lead programme entered Phase I clinical trials in May 2013.
Given Autifony’s focus on modulation of Kv3 channels, which have also been
implicated in other neurological and psychiatric disorders, there are
opportunities for Autifony to investigate these other indications with
compounds with different profiles. Autifony was recently awarded Technology
Strategy Board funding to progress the development of a candidate drug for the
treatment of schizophrenia, working together with academic collaborators at
the Universities of Manchester and Newcastle.
Autifony Therapeutics Limited was formed in 2011 as a spin-out from
GlaxoSmithKline. The company is privately funded by leading venture capital
investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments.
Autifony’s head office is at the Imperial College Incubator in London, and has a
subsidiary with medicinal chemistry and biology labs based in Verona, Italy.

www.autifony.com
7
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php
BIO-Europe 2013
____________________________________________________________

Avillion LLP
Lewis Cameron, Chief Executive Officer
Allison Jeynes-Ellis, Chief Medical Officer

Avillion was registered in London UK in December 2012 and we are fully
financed by the venture capital groups Abingworth and Clarus ventues. We are
a company focused on co-development and financing of late-stage programs,
where we provide partners with 100% financing for regulatory approval studies
with the intent of accelerating the approval of drugs in the US and the EU.

We offer partners an unique and attractive option for the advancement of their
pipeline- where we incur 100% of the clinical and regulatory risk of a program,
thereby enabling partners to limit their P&L burden and have an advantageous
financial position (EPS preservation).

www.avillionllp.com

BIA (UK Bioindustry Association) see page 3

BioPartner UK see page 3

Bristows LLP
Sahar Shepperd, Associate
Matthew Warren, Partner

Bristows is a law firm dedicated to serving businesses with interests in
intellectual property and technology, in industry sectors ranging from
pharmaceuticals, electronics,IT and telecommunications to consumer products,
television and entertainment.

www.bristows.com

8
BOOK MEETINGS WITH UK COMPANIES ATTENDING BIO-EUROPE
http://www.ebdgroup.com/bioeurope/partnering/index.php